

## Press Release

### Apogenix to present at Jefferies 2015 Global Healthcare Conference

**Heidelberg, Germany, June 1, 2015** – Apogenix, a clinical stage biopharmaceutical company, announced today that Thomas Hoeger, Ph.D., Chief Executive Officer, will present at the Jefferies 2015 Global Healthcare Conference in New York. The presentation will take place on Monday, June 1, at 11:30 a.m. EDT at the Grand Hyatt New York, Morosco Room.

#### About Apogenix

Apogenix is a next generation immuno-oncology company focusing on the development of innovative protein therapeutics for the treatment of cancer and other malignant diseases. With a dedicated, highly qualified team, we have built a promising pipeline of drug candidates that target TNFSF-dependent signaling pathways. Apogenix' TNFSF modulators re-establish the body's immune response against tumors and inhibit invasive tumor cell growth.

Since its inception in fall 2005, Apogenix has raised more than 50 million euros from its investors and was awarded public grants totaling 8.5 million euros. The company is based in Heidelberg, Germany.

#### Contact

Thomas Hoeger, Ph.D., CEO/CFO  
Apogenix GmbH  
Phone: +49 (6221) 58 60 80  
E-Mail: [contact@apogenix.com](mailto:contact@apogenix.com)  
Web: [www.apogenix.com](http://www.apogenix.com)

#### Media Contacts

USA:  
Matt Middleman, M.D.  
Russo Partners, LLC  
Phone: +1 (212) 845 4272  
[matt.middleman@russopartnersllc.com](mailto:matt.middleman@russopartnersllc.com)

Europe:  
Raimund Gabriel  
MC Services AG  
Phone: +49 (89) 210 228 30  
[raimund.gabriel@mc-services.eu](mailto:raimund.gabriel@mc-services.eu)